https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ View all drug guidances and details here. en Wed, 14 Oct 2026 12:49:50 +0800 Isomer (https://www.isomer.gov.sg) https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/capivasertib-in-combination-with-fulvestrant-for-hr-positive--her2-negative--locally-advanced-or-metastatic-breast-cancer-with-one-or-more-pik3ca-akt1-pten-alterationurn:isomer:resource:157399-Tue, 06 Oct 2026 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/biologics-for-treating-atopic-dermatitisurn:isomer:resource:423184-Mon, 05 Oct 2026 00:00:00 +0800SkinDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/icatibant-and-sebetralstat-for-treating-hereditary-angioedema-attacksurn:isomer:resource:423192-Mon, 05 Oct 2026 00:00:00 +0800Blood and Immune SystemDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/equecabtagene-autoleucel-for-relapsed-or-refractory-multiple-myelomaurn:isomer:resource:423276-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/selexipag--for-treating-pulmonary-arterial-hypertensionurn:isomer:resource:44161Mon, 05 Oct 2026 00:00:00 +0800CardiovascularDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pembrolizumab-for-treating-resectable-stage-ii--iiia--or-iiib-(t3-4n2)-non-small-cell-lung-cancerurn:isomer:resource:44130Mon, 05 Oct 2026 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pembrolizumab-for-treating-locally-advanced-unresectable-or-metastatic-her2-positive-gastric-or-gastroesophageal-junction-adenocarcinomaurn:isomer:resource:44128Mon, 05 Oct 2026 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pembrolizumab-for-the-adjuvant-treatment-of-renal-cell-carcinomaurn:isomer:resource:44126Mon, 05 Oct 2026 00:00:00 +0800CancerKidneyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pembrolizumab-for-treating-persistent-recurrent-or-metastatic-cervical-cancerurn:isomer:resource:44129Mon, 05 Oct 2026 00:00:00 +0800CancerGynaecologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pembrolizumab-for-treating-high-risk-early-stage-triple-negative-breast-cancerurn:isomer:resource:44127Mon, 05 Oct 2026 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/inavolisib-in-combination-with-palbociclib-and-fulvestrant-for-pik3ca-mutated--hr-positive--her2-negative--locally-advanced-or-metastatic-breast-cancerurn:isomer:resource:157403-Mon, 05 Oct 2026 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/enfortumab-vedotin-in-combination-with-pembrolizumab-for-untreated-locally-advanced-or-metastatic-urothelial-cancerurn:isomer:resource:342780-Mon, 05 Oct 2026 00:00:00 +0800CancerUrologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/rsvpref-maternal-vaccine-for-prevention-of-respiratory-syncytial-virus-associated-lower-respiratory-tract-disease-in-infantsurn:isomer:resource:423208-Mon, 05 Oct 2026 00:00:00 +0800RespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/clesrovimab--for-prevention-of-respiratory-syncytial-virus-associated-lower-respiratory-tract-disease-in-infants-during-their-first-rsv-season-urn:isomer:resource:423203-Mon, 05 Oct 2026 00:00:00 +0800RespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/brexucabtagene-autoleucel-for-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemiaurn:isomer:resource:423216-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/osimertinib---for-maintenance-treatment-of-locally-advanced--unresectable-egfr-mutation-positive-non-small-cell-lung-cancer-during-or-following-chemoradiation-therapy-urn:isomer:resource:423289-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nivolumab-and-relatlimab-for-first-line-treatment-of-unresectable-or-metastatic-melanomaurn:isomer:resource:423288-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/durvalumab---for-treating-resectable-gastric-or-gastroesophageal-junction-adenocarcinomaurn:isomer:resource:423277-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nivolumab-in-combination-with-ipilimumab-for-untreated-unresectable-or-metastatic-colorectal-cancerurn:isomer:resource:423322-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pembrolizumab-for-untreated-locally-advanced-cervical-cancerurn:isomer:resource:423294-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pembrolizumab--for-treating-resectable-locally-advanced-head-and-neck-squamous-cell-carcinomaurn:isomer:resource:423290-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nivolumab-for-treating-resectable--tumours-4-cm-or-node-positive--non-small-cell-lung-cancerurn:isomer:resource:423287-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nivolumab-in-combination-with-ipilimumab-for-treating-unresectable-or-advanced-hepatocellular-carcinomaurn:isomer:resource:423285-Mon, 05 Oct 2026 00:00:00 +0800CancerLiverDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/durvalumab-for-treating-resectable-muscle-invasive-bladder-cancerurn:isomer:resource:423279-Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nivolumab-in-combination-with-ipilimumab-and-chemotherapy-for-untreated-metastatic-or-recurrent-non-small-cell-lung-cancer-in-patients-whose-tumours-express-pd-l1-with-a-tumour-proportion-score--1--with-no-egfr-or-alk-genomic-tumour-mutationsurn:isomer:resource:157431-Mon, 05 Oct 2026 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/update-of-moh-list-of-subsidised-drugs-to-include-treatments-for-various-cancer-conditionsurn:isomer:resource:44184Mon, 05 Oct 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-drugs-for-previously-treated-advanced-hepatocellular-carcinomaurn:isomer:resource:44146Mon, 05 Oct 2026 00:00:00 +0800CancerLiverDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-drugs-for-previously-treated-advanced-gastric-cancerurn:isomer:resource:44145Mon, 05 Oct 2026 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/immune-checkpoint-inhibitors-and-brak-mek-inhibitors-for-treating-advanced-malignant-melanomaurn:isomer:resource:44095Mon, 05 Oct 2026 00:00:00 +0800CancerSkinDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/cabozantinib-in-combination-with-nivolumab-for-previously-untreated-advanced-renal-cell-cancerurn:isomer:resource:44056Mon, 05 Oct 2026 00:00:00 +0800CancerKidneyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/-belzutifan-for-von-hippel-lindau-disease-with-associated-non-metastatic-renal-cell-carcinoma--central-nervous-system-hemangioblastomas--or-pancreatic-neuroendocrine-tumours-urn:isomer:resource:342739 Wed, 01 Jul 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/acalabrutinib-in-combination-with-bendamustine-and-rituximab-for-previously-untreated-mantle-cell-lymphomaurn:isomer:resource:342738 Wed, 01 Jul 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/biologics-as-add-on-therapy-for-treating-chronic-rhinosinusitis-with-nasal-polyps--urn:isomer:resource:342740 Wed, 01 Jul 2026 00:00:00 +0800RespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/cabozantinib-for-previously-treated-well-differentiated-pancreatic-or-extra-pancreatic-neuroendocrine-tumours-urn:isomer:resource:342759 Wed, 01 Jul 2026 00:00:00 +0800CancerEndocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/disease-modifying-therapies-for-treating-multiple-sclerosisurn:isomer:resource:44072Wed, 01 Jul 2026 00:00:00 +0800Blood and Immune SystemNeurologyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/durvalumab-for-limited-stage-small-cell-lung-cancer-urn:isomer:resource:342764 Wed, 01 Jul 2026 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/elacestrant-for-er-positive--her2-negative--locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation-urn:isomer:resource:342769 Wed, 01 Jul 2026 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/eplontersen-and-vutrisiran-for-hereditary-transthyretin-amyloidosis-with-polyneuropathyurn:isomer:resource:157393-Wed, 01 Jul 2026 00:00:00 +0800CardiovascularNeurologyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/glofitamab-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-not-otherwise-specified-in-patients-who-are-not-candidates-for-autologous-stem-cell-transplanturn:isomer:resource:342781-Wed, 01 Jul 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/liposomal-irinotecan-for-first-line-treatment-of-metastatic-adenocarcinoma-of-the-pancreasurn:isomer:resource:342782-Wed, 01 Jul 2026 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/maribavir-for-treating-refractory-or-drug-intolerant-cytomegalovirus-infection-after-transplanturn:isomer:resource:342784-Wed, 01 Jul 2026 00:00:00 +0800InfectionsDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nirsevimab-for-prevention-of-respiratory-syncytial-virus-associated-lower-respiratory-tract-disease-in-infants-during-their-first-rsv-seasonurn:isomer:resource:342788-Wed, 01 Jul 2026 00:00:00 +0800InfectionsRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nusinersen-and-risdiplam-for-treating-spinal-muscular-atrophyurn:isomer:resource:44118Wed, 01 Jul 2026 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/selpercatinib-for-advanced-or-metastatic-thyroid-cancer-with-ret-alterationsurn:isomer:resource:342786-Wed, 01 Jul 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/selpercatinib-for-locally-advanced-or-metastatic-ret-fusion-positive-non-small-cell-lung-cancerurn:isomer:resource:342785-Wed, 01 Jul 2026 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tislelizumab-for-untreated-her2-negative--unresectable-advanced-gastric-or-gastroesophageal-junction-adenocarcinomaurn:isomer:resource:342787-Wed, 01 Jul 2026 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/vutrisiran-for-transthyretin-amyloid-cardiomyopathyurn:isomer:resource:342789-Wed, 01 Jul 2026 00:00:00 +0800CardiovascularDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/zolbetuximab-for-untreated-her2-negative--claudin-18-2-positive--unresectable-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-urn:isomer:resource:157428-Wed, 01 Jul 2026 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/aflibercept-bevacizumab-and-ramucirumab-for-treating-metastatic-colorectal-cancerurn:isomer:resource:44036Mon, 01 Jun 2026 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/alectinib-for-adjuvant-treatment-of-resectable--alk-mutation-positive-non-small-cell-lung-cancerurn:isomer:resource:65359-Mon, 01 Jun 2026 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/blinatumomab-for-newly-diagnosed-b-precursor-acute-lymphoblastic-leukaemia-in-the-consolidation-phase-of-chemotherapy-urn:isomer:resource:157429-Mon, 01 Jun 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/blinatumomab-for-treating-relapsed-or-refractory-b-precursor-acute-lymphoblastic-leukaemiaurn:isomer:resource:44045-Mon, 01 Jun 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/brentuximab-vedotin-for-treating-t-cell-lymphomaurn:isomer:resource:44052Mon, 01 Jun 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/dabrafenib-in-combination-with-trametinib-for-low-grade-glioma-and-relapsed-or-refractory-high-grade-glioma--with-braf-v600e-mutationsurn:isomer:resource:157430-Mon, 01 Jun 2026 00:00:00 +0800CancerNeurologyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/dabrafenib-in-combination-with-trametinib-for-treating-braf-v600-mutation-positive-anaplastic-thyroid-cancerurn:isomer:resource:44062Mon, 01 Jun 2026 00:00:00 +0800CancerEndocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/dostarlimab--for-treating-dmmr-or-msi-h-primary-advanced-or-recurrent-endometrial-cancerurn:isomer:resource:44074Mon, 01 Jun 2026 00:00:00 +0800CancerGynaecologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/durvalumab-in-combination-with-tremelimumab-for-treating-unresectable-hepatocellular-carcinomaurn:isomer:resource:44075Mon, 01 Jun 2026 00:00:00 +0800CancerLiverDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/gemtuzumab-ozogamicin-for-untreated-de-novo-cd33-positive-acute-myeloid-leukaemiaurn:isomer:resource:44088Mon, 01 Jun 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/lenvatinib-and-sorafenib-for-treating-advanced-hepatocellular-carcinomaurn:isomer:resource:44107Mon, 01 Jun 2026 00:00:00 +0800CancerLiverDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/lenvatinib-and-sorafenib-for-treating-differentiated-thyroid-cancerurn:isomer:resource:44108Mon, 01 Jun 2026 00:00:00 +0800CancerEndocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/momelotinib-for-treating-myelofibrosis-in-patients-with-moderate-to-severe-anaemiaurn:isomer:resource:88763-Mon, 01 Jun 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nivolumab-for-treating-gastroesophageal-cancersurn:isomer:resource:44115Mon, 01 Jun 2026 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/olaparib-for-treating-germline-brca-mutated-her2-negative-high-risk-early-breast-cancerurn:isomer:resource:44119Mon, 01 Jun 2026 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/parp-inhibitors-and-bevacizumab-for-treating-advanced-ovarian-cancerurn:isomer:resource:44124Mon, 01 Jun 2026 00:00:00 +0800CancerGynaecologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/polatuzumab-vedotin-for-previously-untreated-diffuse-large-b-cell-lymphomaurn:isomer:resource:44132Mon, 01 Jun 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/poly-(adp-ribose)-polymerase-inhibitors-for-treating-brca-mutated-her2-negative-advanced-breast-cancerurn:isomer:resource:44134Mon, 01 Jun 2026 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-drugs-for-acute-lymphoblastic-leukaemiaurn:isomer:resource:44143Mon, 01 Jun 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-drugs-for-treating-advanced-urothelial-carcinomaurn:isomer:resource:44149Mon, 01 Jun 2026 00:00:00 +0800CancerUrologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/sacituzumab-govitecan-for-unresectable-locally-advanced-or-metastatic-hr-positive--her2-negative-breast-cancerurn:isomer:resource:44158Mon, 01 Jun 2026 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tislelizumab-for-treating-locally-advanced-or-metastatic-non-squamous-non-small-cell-lung-cancer-without-egfr-or-alk-genomic-tumour-aberrationsurn:isomer:resource:76669-Mon, 01 Jun 2026 00:00:00 +0800Drug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tislelizumab-for-treating-non-small-cell-lung-cancer--oesophageal-squamous-cell-carcinoma--and-nasopharyngeal-carcinomaurn:isomer:resource:76670-Mon, 01 Jun 2026 00:00:00 +0800Drug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/toripalimab-for-first-line-systemic-treatment-of-recurrent-or-metastatic-nasopharyngeal-carcinomaurn:isomer:resource:88767-Mon, 01 Jun 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tyrosine-kinase-inhibitors-for-treating-met-mutation-positive-metastatic-non-small-cell-lung-cancerurn:isomer:resource:44182Mon, 01 Jun 2026 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nirmatrelvir-and-ritonavir-combination-for-treating-mild-to-moderate-covid-19urn:isomer:resource:44114Wed, 01 Apr 2026 00:00:00 +0800InfectionsDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/amivantamab-for-previously-treated--locally-advanced-or-metastatic-egfr-exon-19-deletion-or-exon-21-l858r-substitution-mutation-positive-non-small-cell-lung-cancerurn:isomer:resource:157394-Fri, 06 Feb 2026 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/amivantamab-for-previously-untreated--locally-advanced-or-metastatic-egfr-exon-20-insertion-mutation-positive-non-small-cell-lung-cancerurn:isomer:resource:157395-Fri, 06 Feb 2026 00:00:00 +0800Drug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/asciminib-for-philadelphia-chromosome-positive-chronic-myeloid-leukaemia-in-chronic-phase-after-two-or-more-tyrosine-kinase-inhibitorsurn:isomer:resource:65358-Fri, 06 Feb 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/biologics-as-add-on-therapy-for-severe-asthmaurn:isomer:resource:44041Fri, 06 Feb 2026 00:00:00 +0800RespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/complement-inhibitors-for-treating-paroxysmal-nocturnal-haemoglobinuria-and-atypical-haemolytic-uraemic-syndromeurn:isomer:resource:157392-Fri, 06 Feb 2026 00:00:00 +0800Blood and Immune SystemDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/donanemab-and-lecanemab-for-treating-mild--cognitive-impairment-and-mild-dementia-due-to-alzheimer-s-diseaseurn:isomer:resource:157405-Fri, 06 Feb 2026 00:00:00 +0800NeurologyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/novel-oral-anticoagulants-(noacs)-for-the-prevention-of-stroke-and-systemic-embolism-in-non-valvular-atrial-fibrillationurn:isomer:resource:44117Fri, 06 Feb 2026 00:00:00 +0800CardiovascularWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/non-vitamin-k-antagonist-oral-anti-coagulation-agents-(noacs)-for-the-treatment-and-secondary-prevention-of-venous-thromboembolismurn:isomer:resource:44116Fri, 06 Feb 2026 00:00:00 +0800CardiovascularWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/omalizumab-biosimilar-for-treating-inflammatory-conditionsurn:isomer:resource:157391-Fri, 06 Feb 2026 00:00:00 +0800Blood and Immune SystemRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/omalizumab-for-treating-antihistamine-resistant-chronic-spontaneous-urticariaurn:isomer:resource:44120Fri, 06 Feb 2026 00:00:00 +0800SkinWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ribociclib-for-the-adjuvant-treatment-of-hr-positive--her2-negative-stage-ii-and-iii-early-breast-cancer-at-high-risk-of-recurrenceurn:isomer:resource:157420-Fri, 06 Feb 2026 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/sodium-zirconium-cyclosilicate-for-treating-hyperkalaemiaurn:isomer:resource:44165Fri, 06 Feb 2026 00:00:00 +0800KidneyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/talquetamab-for-relapsed-or-refractory-multiple-myeloma-urn:isomer:resource:157426-Fri, 06 Feb 2026 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tofacitinib-ustekinumab-and-vedolizumab-for-treating-inflammatory-bowel-diseaseurn:isomer:resource:44175Fri, 06 Feb 2026 00:00:00 +0800Gastrointestinal tractWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/trastuzumab-deruxtecan-for-unresectable-or-metastatic-her2-positive-solid-tumours-after-at-least-one-prior-line-of-systemic-therapyurn:isomer:resource:157434-Fri, 06 Feb 2026 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/trastuzumab-deruxtecan-for-unresectable-or-metastatic-non-small-cell-lung-cancer-whose-tumours-have-activating-her2--erbb2--mutations-and-who-have-received-a-prior-systemic-therapyurn:isomer:resource:157441-Fri, 06 Feb 2026 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ustekinumab-biosimilar-for-treating-inflammatory-conditionsurn:isomer:resource:157680-Fri, 06 Feb 2026 00:00:00 +0800Gastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ustekinumab-for-the-treatment-of-chronic-plaque-psoriasis-and-psoriatic-arthritisurn:isomer:resource:44186Fri, 06 Feb 2026 00:00:00 +0800MusculoskeletalSkinWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/daratumumab-based-regimens-for-newly-diagnosed-multiple-myelomaurn:isomer:resource:44064Sat, 01 Nov 2025 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-drugs-for-previously-treated-multiple-myelomaurn:isomer:resource:44147Sat, 01 Nov 2025 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/aflibercept-and-faricimab-for-treating-macular-oedema-secondary-to-retinal-vein-occlusionurn:isomer:resource:88754-Tue, 16 Sep 2025 00:00:00 +0800EyeDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/anti-vascular-endothelial-growth-factors-for-treating-diabetic-macular-oedema-and-age-related-macular-degenerationurn:isomer:resource:44037Tue, 16 Sep 2025 00:00:00 +0800EyeDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/botulinum-toxin-a-for-treating-adults-with-focal-spasticity-of-the-lower-limbs-associated-with-stroke-in-adultsurn:isomer:resource:44047Tue, 16 Sep 2025 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/botulinum-toxin-a-for-the-management-of-focal-spasticity-of-the-upper-limbs-associated-with-stroke-in-adultsurn:isomer:resource:44046Tue, 16 Sep 2025 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/botulinum-toxin-a-for-treating-blepharospasm-or-hemifacial-spasmurn:isomer:resource:44048Tue, 16 Sep 2025 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/botulinum-toxin-a-for-treating-cervical-dystoniaurn:isomer:resource:44049Tue, 16 Sep 2025 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/botulinum-toxin-a-for-treating-focal-spasticity-of-the-upper-or-lower-limbs-in-children-with-cerebral-palsyurn:isomer:resource:44050Tue, 16 Sep 2025 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/datopotamab-deruxtecan-for-previously-treated-unresectable-or-metastatic-hr-positive--her2-negative-breast-cancerurn:isomer:resource:88739-Tue, 16 Sep 2025 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/durvalumab-with-or-without-olaparib-for-treating-primary-advanced-or-recurrent-endometrial-cancerurn:isomer:resource:88762-Tue, 16 Sep 2025 00:00:00 +0800CancerGynaecologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/epcoritamab-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapyurn:isomer:resource:65355-Tue, 16 Sep 2025 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/finerenone-for-treating-chronic-kidney-disease-and-albuminuria-associated-with-type-2-diabetesurn:isomer:resource:65349-Tue, 16 Sep 2025 00:00:00 +0800Endocrine and metabolicKidneyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/fruquintinib-for-previously-treated-metastatic-colorectal-cancerurn:isomer:resource:65362-Tue, 16 Sep 2025 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/onasemnogene-abeparvovec-for-treating-spinal-muscular-atrophyurn:isomer:resource:83969-Tue, 16 Sep 2025 00:00:00 +0800MusculoskeletalNeurologyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/sotorasib-for-previously-treated-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancerurn:isomer:resource:88764-Tue, 16 Sep 2025 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/sucroferric-oxyhydroxide-for-treating-hyperphosphataemia-in-patients-with-end-stage-renal-disease-on-dialysisurn:isomer:resource:88768-Tue, 16 Sep 2025 00:00:00 +0800KidneyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/talazoparib-in-combination-with-enzalutamide-for-treating-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancerurn:isomer:resource:88765-Tue, 16 Sep 2025 00:00:00 +0800CancerUrologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/bevacizumab-biosimilar-for-treating-different-types-of-cancerurn:isomer:resource:44042Fri, 01 Aug 2025 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/atogepant-and-rimegepant-for-prophylaxis-of-migraineurn:isomer:resource:65343-Wed, 04 Jun 2025 00:00:00 +0800NeurologyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/axicabtagene-ciloleucel--for-relapsed-or-refractory-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapyurn:isomer:resource:44039Wed, 04 Jun 2025 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/crisaborole-ointment-for-treating-atopic-dermatitisurn:isomer:resource:65352-Wed, 04 Jun 2025 00:00:00 +0800SkinDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/mavacamten-for-treating-obstructive-hypertrophic-cardiomyopathyurn:isomer:resource:65351-Wed, 04 Jun 2025 00:00:00 +0800CardiovascularDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/romosozumab-and-teriparatide-for-treating-osteoporosisurn:isomer:resource:44155Wed, 04 Jun 2025 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/teriparatide-biosimilar-for-treating-osteoporosisurn:isomer:resource:65353-Wed, 04 Jun 2025 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/dutasteride-tamsulosin-alfuzosin-and-dutasteride-tamsulosin-combination-for-treating-benign-prostatic-hyperplasiaurn:isomer:resource:44076Tue, 01 Apr 2025 00:00:00 +0800UrologicalWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/axicabtagene-ciloleucel--for-second-line-relapsed-or-refractory-large-b-cell-lymphomaurn:isomer:resource:44040Mon, 17 Feb 2025 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/deucravacitinib-for-moderate-to-severe-chronic-plaque-psoriasisurn:isomer:resource:44069Mon, 17 Feb 2025 00:00:00 +0800Blood and Immune SystemSkinDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/glofitamab-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapyurn:isomer:resource:44090Mon, 17 Feb 2025 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tisagenlecleucel-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-after-two-or-more-lines-of-systemic-therapyurn:isomer:resource:44174Mon, 17 Feb 2025 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/triple-therapy-inhalers-for-treating-asthma-or-chronic-obstructive-pulmonary-diseaseurn:isomer:resource:44180Mon, 17 Feb 2025 00:00:00 +0800RespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pneumococcal-conjugate-vaccines-(15-valent-and-20-valent)-for-the-prevention-of-pneumococcal-disease-in-adultsurn:isomer:resource:44131Mon, 10 Feb 2025 00:00:00 +0800InfectionsVaccinesDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/recombinant-zoster-vaccine-for-the-prevention-of-herpes-zoster-and-post-herpetic-neuralgiaurn:isomer:resource:44140Mon, 10 Feb 2025 00:00:00 +0800InfectionsVaccinesDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/cabotegravir-with-rilpivirine---for-treating-human-immunodeficiency-virus-type-1-(hiv-1)-infectionurn:isomer:resource:44055Fri, 13 Sep 2024 00:00:00 +0800InfectionsDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/darolutamide--for-treating-prostate-cancerurn:isomer:resource:44066Fri, 13 Sep 2024 00:00:00 +0800CancerUrologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/infliximab-biosimilar-for-treating-inflammatory-conditionurn:isomer:resource:44096Fri, 13 Sep 2024 00:00:00 +0800Gastrointestinal tractMusculoskeletalSkinDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-drugs-for-prostate-cancerurn:isomer:resource:44148Fri, 13 Sep 2024 00:00:00 +0800Withdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/subcutaneous-infliximab-biosimilar--for-treating-inflammatory-conditionsurn:isomer:resource:44167Fri, 13 Sep 2024 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/trastuzumab-deruxtecan-for-her2-low-unresectable-and-or-metastatic-breast-cancer-after-at-least-one-prior-line-of-chemotherapyurn:isomer:resource:44177Fri, 13 Sep 2024 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/endothelin-receptor-antagonists-for-treating-pulmonary-arterial-hypertensionurn:isomer:resource:44080Mon, 02 Sep 2024 00:00:00 +0800CardiovascularDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tisagenlecleucel-for-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukaemiaurn:isomer:resource:44173Thu, 01 Aug 2024 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/burosumab-for-treating-x-linked-hypophosphataemiaurn:isomer:resource:44054Tue, 04 Jun 2024 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/calcitonin-gene-related-peptide-monoclonal-antibodies-for-prophylaxis-of-migraineurn:isomer:resource:44057Tue, 04 Jun 2024 00:00:00 +0800NeurologyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/direct-acting-antiviral-agents-for-treating-chronic-hepatitis-curn:isomer:resource:44071Tue, 04 Jun 2024 00:00:00 +0800InfectionsDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/enzyme-replacement-therapies-for-fabry-diseaseurn:isomer:resource:44081Tue, 04 Jun 2024 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/prostaglandin-analogue-with-timolol-fixed-dose-combination-eye-drops-for-treatment-of-open-angle-glaucoma-or-ocular-hypertensionurn:isomer:resource:44136Tue, 04 Jun 2024 00:00:00 +0800EyeDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ruxolitinib-for-treating-graft-versus-host-diseaseurn:isomer:resource:44156Tue, 04 Jun 2024 00:00:00 +0800Blood and Immune SystemDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tafamidis-for-treating-transthyretin-amyloid-cardiomyopathyurn:isomer:resource:44169Tue, 04 Jun 2024 00:00:00 +0800CardiovascularDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tolvaptan-for-treating-autosomal-dominant-polycystic-kidney-diseaseurn:isomer:resource:44176Tue, 04 Jun 2024 00:00:00 +0800KidneyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/vortioxetine-for-treatment-of-depressionurn:isomer:resource:44188Tue, 04 Jun 2024 00:00:00 +0800Mental Health and BehaviourDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/osimertinib-for-treating-egfr-mutation-positive-non-small-cell-lung-cancerurn:isomer:resource:44122Thu, 01 Feb 2024 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/abrocitinib-baricitinib-upadacitinib-and-dupilumab-for-treating-atopic-dermatitisurn:isomer:resource:44032Tue, 02 Jan 2024 00:00:00 +0800SkinDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/acalabrutinib-bortezomib-and-ibrutinib-for-treating-mantle-cell-lymphomaurn:isomer:resource:44033Tue, 02 Jan 2024 00:00:00 +0800Blood and Immune SystemCancerWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/everolimus-lanreotide-octreotide-and-sunitinib-for-treating-advanced-neuroendocrine-tumoursurn:isomer:resource:44082Tue, 02 Jan 2024 00:00:00 +0800CancerEndocrine and metabolicWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ferric-carboxymaltose-for-treating-iron-deficiency-anaemiaurn:isomer:resource:44085Tue, 02 Jan 2024 00:00:00 +0800Blood and Immune SystemDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ferric-derisomaltose-for-treating-iron-deficiency-anemiaurn:isomer:resource:44086Tue, 02 Jan 2024 00:00:00 +0800Blood and Immune SystemDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/insulin-aspart-(fiasp)-for-treating-diabetes-mellitusurn:isomer:resource:44098Tue, 02 Jan 2024 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pcsk9-inhibitors-for-treating-hypercholesterolaemiaurn:isomer:resource:44125Tue, 02 Jan 2024 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/regorafenib-and-sunitinib-for-treating-advanced-gastrointestinal-stromal-tumoursurn:isomer:resource:44141Tue, 02 Jan 2024 00:00:00 +0800CancerGastrointestinal tractWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-drugs-for-chronic-lymphocytic-leukaemiaurn:isomer:resource:44144Tue, 02 Jan 2024 00:00:00 +0800Blood and Immune SystemCancerWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/sglt2-inhibitors-for-treating-heart-failure-with-reduced-ejection-fraction-and-chronic-kidney-diseaseurn:isomer:resource:44162Tue, 02 Jan 2024 00:00:00 +0800CardiovascularKidneyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/sodium-glucose-co-transporter-2-(sglt2)-inhibitors-for-type-2-diabetes-mellitusurn:isomer:resource:44164Tue, 02 Jan 2024 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tyrosine-kinase-inhibitors-immune-checkpoint-inhibitors-and-everolimus-for-treating-advanced-renal-cell-cancerurn:isomer:resource:44183Tue, 02 Jan 2024 00:00:00 +0800CancerKidneyWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/dexamethasone-intravitreal-implant-for-treating-diabetic-macular-oedema-retinal-vein-occlusion-and-non-infectious-uveitisurn:isomer:resource:44070Fri, 01 Sep 2023 00:00:00 +0800EyeDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/long-acting-erythropoiesis-stimulating-agents-for-treating-anaemia-in-chronic-kidney-diseaseurn:isomer:resource:44109Fri, 01 Sep 2023 00:00:00 +0800Withdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/pralsetinib-for-treating-ret-fusion-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancerurn:isomer:resource:44135Fri, 01 Sep 2023 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-drugs-for-treating-early-or-advanced-her2-positive-breast-cancerurn:isomer:resource:44150Fri, 01 Sep 2023 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/trastuzumab-deruxtecan-for-previously-treated-her2-positive-metastatic-breast-cancerurn:isomer:resource:44178Fri, 01 Sep 2023 00:00:00 +0800 BreastCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/trastuzumab-deruxtecan-for-treating-her2-positive-advanced-gastric-cancer-after-two-or-more-therapiesurn:isomer:resource:44179Fri, 01 Sep 2023 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ixekizumab-and-secukinumab-for-treating-active-non-radiographic-axial-spondyloarthritisurn:isomer:resource:44103Thu, 01 Jun 2023 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/review-of-cancer-supportive-care-medicinesurn:isomer:resource:44151Sat, 01 Apr 2023 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/daratumumab-for-treating-newly-diagnosed-light-chain-(al)-amyloidosisurn:isomer:resource:44065Wed, 08 Feb 2023 00:00:00 +0800CancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/echinocandins-for-treating-invasive-candidiasisurn:isomer:resource:44077Wed, 08 Feb 2023 00:00:00 +0800InfectionsDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/inhaled-corticosteroids-with-long-acting-beta-2-agonists-for-treating-asthmaurn:isomer:resource:44097Wed, 08 Feb 2023 00:00:00 +0800RespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/palivizumab-for-preventing-serious-lower-respiratory-tract-disease-caused-by-respiratory-syncytial-virusurn:isomer:resource:44123Wed, 08 Feb 2023 00:00:00 +0800InfectionsRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/abiraterone-for-treating-metastatic-prostate-cancerurn:isomer:resource:44031Mon, 19 Dec 2022 00:00:00 +0800CancerUrologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/acarbose-for-treating-type-2-diabetes-mellitusurn:isomer:resource:44034Mon, 19 Dec 2022 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ciclosporin-0-1-eye-drops-for-treating-severe-keratitis-in-dry-eye-diseaseurn:isomer:resource:44060Mon, 19 Dec 2022 00:00:00 +0800EyeDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ciclosporin-eye-drops-for-treating-severe-vernal-keratoconjunctivitisurn:isomer:resource:44061Mon, 19 Dec 2022 00:00:00 +0800EyeDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/dolutegravir-with-lamivudine-for-treating-human-immunodeficiency-virus-type-1-(hiv-1)-infectionurn:isomer:resource:44073Mon, 19 Dec 2022 00:00:00 +0800InfectionsDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/glp-1-receptor-agonist-injections-for-treating-type-2-diabetes-mellitusurn:isomer:resource:44091Mon, 19 Dec 2022 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/nicotine-replacement-therapies-to-aid-smoking-cessationurn:isomer:resource:44112Mon, 19 Dec 2022 00:00:00 +0800RespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/recombinant-blood-products-for-prophylaxis-and-management-of-haemophilia-a-and-burn:isomer:resource:44139Mon, 19 Dec 2022 00:00:00 +0800Blood and Immune SystemDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/regorafenib-and-trifluridine-tipiracil-for-previously-treated-metastatic-colorectal-cancerurn:isomer:resource:44142Mon, 19 Dec 2022 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/guselkumab-ixekizumab-and-secukinumab-for-treating-chronic-plaque-psoriasisurn:isomer:resource:44093Wed, 31 Aug 2022 00:00:00 +0800Blood and Immune SystemSkinDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/insulin-glargine-biosimilar-(basaglar)-for-the-treatment-of-type-1-and-type-2-diabetes-mellitusurn:isomer:resource:44099Wed, 31 Aug 2022 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ixekizumab-and-secukinumab-for-treating-active-ankylosing-spondylitisurn:isomer:resource:44102Wed, 31 Aug 2022 00:00:00 +0800Blood and Immune SystemMusculoskeletalWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ixekizumab-and-secukinumab-for-treating-active-psoriatic-arthritisurn:isomer:resource:44104Wed, 31 Aug 2022 00:00:00 +0800Blood and Immune SystemMusculoskeletalSkinWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tyrosine-kinase-inhibitors-for-treating-alk-mutation-positive-advanced-non-small-cell-lung-cancerurn:isomer:resource:44181Wed, 31 Aug 2022 00:00:00 +0800CancerRespiratoryWithdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/bevacizumab-for-treating-persistent-recurrent-or-metastatic-cervical-cancerurn:isomer:resource:44043Tue, 12 Jul 2022 00:00:00 +0800CancerGynaecologicalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/cetuximab-and-panitumumab-for-treating-ras-wild-type-colorectal-cancerurn:isomer:resource:44059Tue, 12 Jul 2022 00:00:00 +0800CancerGastrointestinal tractDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/polatuzumab-vedotin-for-treating-relapsed-or-refractory-diffuse-large-b-cell-lymphomaurn:isomer:resource:44133Tue, 12 Jul 2022 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ruxolitinib-for-treating-polycythaemia-veraurn:isomer:resource:44157Tue, 12 Jul 2022 00:00:00 +0800Blood and Immune SystemCancerDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/biologics-and-janus-kinase-inhibitors-after-conventional-disease-modifying-antirheumatic-drugs-for-treating-rheumatoid-arthritisurn:isomer:resource:44044Fri, 01 Jul 2022 00:00:00 +0800Blood and Immune SystemMusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/denosumab-for-the-treatment-of-postmenopausal-women-with-osteoporosis-at-high-risk-of-fractureurn:isomer:resource:44068Fri, 01 Jul 2022 00:00:00 +0800MusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/emicizumab-prophylaxis-for-patients-with-haemophilia-aurn:isomer:resource:44079Fri, 01 Jul 2022 00:00:00 +0800Blood and Immune SystemDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/sitagliptin-for-treating-type-2-diabetes-mellitusurn:isomer:resource:44163Fri, 01 Jul 2022 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/carbonic-anhydrase-inhibitor-eye-drops-for-treating-open-angle-glaucoma-or-ocular-hypertensionurn:isomer:resource:44058Fri, 01 Apr 2022 00:00:00 +0800EyeDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/high-strength-insulin-glargine-for-treating-type-1-and-2-diabetes-mellitusurn:isomer:resource:44094Fri, 01 Apr 2022 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/botulinum-toxin-type-a-for-the-prophylaxis-of-headaches-in-adults-with-chronic-migraineurn:isomer:resource:44051Tue, 04 Jan 2022 00:00:00 +0800NeurologyDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/eltrombopag-for-treating-immune-thrombocytopenia-and-severe-aplastic-anaemiaurn:isomer:resource:44078Tue, 04 Jan 2022 00:00:00 +0800Blood and Immune SystemDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/ranibizumab-for-treating-age-related-macular-degeneration-diabetic-macular-oedema-and-retinal-vein-occlusionurn:isomer:resource:44138Tue, 04 Jan 2022 00:00:00 +0800EyeDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/sacubitril-valsartan-for-treating-chronic-heart-failure-with-reduced-ejection-fractionurn:isomer:resource:44159Tue, 04 Jan 2022 00:00:00 +0800CardiovascularDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/tyrosine-kinase-inhibitors-for-renal-cell-carcinoma--rcc-urn:isomer:resource:44526 Tue, 04 Jan 2022 00:00:00 +0800Withdrawn https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/dacomitinib-for-treating-egfr-mutation-positive-non-small-cell-lung-cancerurn:isomer:resource:44063Tue, 17 Aug 2021 00:00:00 +0800CancerRespiratoryDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/golimumab-for-the-treatment-of-rheumatoid-arthritis-psoriatic-arthritis-ankylosing-spondylitis-and-ulcerative-colitisurn:isomer:resource:44092Mon, 18 Jan 2021 00:00:00 +0800Gastrointestinal tractMusculoskeletalDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/metformin-extended-release-for-treating-type-2-diabetes-mellitusurn:isomer:resource:44110Mon, 18 Jan 2021 00:00:00 +0800Endocrine and metabolicDrug guidance https://www.ace-hta.gov.sg/healthcare-professionals/ace-technology-guidance/drug-guidance/rituximab-for-treating-non-hodgkin-s-lymphoma-and-chronic-lymphocytic-leukaemiaurn:isomer:resource:44153Mon, 18 Jan 2021 00:00:00 +0800Blood and Immune SystemCancerDrug guidance